Hepatotoxicity associated with nevirapine use

被引：84
作者：
Baylor, MS [1 ]
Johann-Liang, R [1 ]
机构：
[1] US FDA, Div Antiviral Drug Prod, Rockville, MD 20857 USA
来源：
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES | 2004年 / 35卷 / 05期
关键词：
D O I：
10.1097/00126334-200404150-00014
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：538 / 539
页数：2
相关论文
共 9 条
  • [1] BARLETT J, SEVERE LIVER TOXICIT
  • [2] BAYLOR M, 2003, MED OFF REV
  • [3] *BOEHR ING PHARM I, VIR PACK INS
  • [4] BOXWELL D, 2001, MMWR-MORBID MORTAL W, V49, P1153
  • [5] HAVERKOS H, 2002, MED OFFICERS REV
  • [6] IMPERIALE SM, 2002, 4 INT WORKSH ADV EV
  • [7] LYONS F, 2003, INT AIDS SOC JUL 13
  • [8] STERN J, 2002, 14 INT AIDS C JUL 7
  • [9] A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients
    Stern, JO
    Robinson, PA
    Love, J
    Lanes, S
    Imperiale, MS
    Mayers, DL
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2003, 34 : S21 - S33
1